Hydrophobic acrylic IOL corrects corneal astigmatism

Article

A new hydrophobic acrylic IOL is an effective, safe and predictable method for the correction of corneal astigmatism in patients undergoing routine cataract surgery.

A new hydrophobic acrylic IOL is an effective, safe and predictable method for the correction of corneal astigmatism in patients undergoing routine cataract surgery, according to recently published data.

Dr Amy L. Sheppard et al., School of Life and Health Sciences, Aston University, Birmingham, UK, completed a cohort study in four hospital eye clinics in Europe on 67 eyes of 60 patients.

The outcome measures included uncorrected distance visual acuity (UDVA), corrected distance visual acuity, manifest refraction and keratometry. The team also documented individual patient satisfaction with uncorrected vision and the surgeon’s evaluation of ease of handling and performance of the IOL.

Four to eight weeks after cataract surgery, the mean UDVA was 0.15 logMAR ± 0.17 and UDVA was 20/40 or better in 88% of eyes. Mean refractive cylinder decreased significantly postoperatively from −1.91 ± 1.07 D to −0.67 ± 0.54 D. However, there was no change in keratometric cylinder. The good UDVA resulted in high levels of patient satisfaction.

The abstract for this study has been published in the Journal of Cataract and Refractive Surgery.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.